Observational study of FOLFIRINOX therapy for unresectable and recurrence pancreatic cancer

Observational study of FOLFIRINOX therapy for unresectable and recurrence pancreatic cancer - JASPAC 06

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014658

Enrollment

329

Registered

2014-07-26

Start date

2014-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable and recurrence pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Diagnosed as unresectable and recurrence pancreatic cancer, and received or will be received FOLFIRINOX therapy (oxaliplatin, irinotecan, levofolinate calcium and fluorouracil) between 20th Dec. 2013 and 19th Dec. 2014. 2) Written informed consent, but it is not necessary for the patients who discontinued protocol therapy.

Exclusion criteria

Exclusion criteria: 1) Histologically proven not to be a malignant pancreatic exocrine tumor 2) Not administered all of oxaliplatin, irinotecan, levofolinate calcium and fluorouracil

Design outcomes

Primary

Measure	Time frame
adverse events severe adverse events	—

Secondary

Measure	Time frame
dose intensity, the reasons for dose reduction and delay, progression free survival, overall survival	—

Countries

Japan

Contacts

Public ContactAkiko Todaka

Shizuoka Cancer Center Division of GI Oncology and Endoscopy

a.todaka@scchr.jp055-989-5222

Outcome results